Camurus (OTC:CAMRF) and Eli Lilly and Company (NYSE:LLY) entered into a collaboration and license agreement. This agreement grants Lilly exclusive, worldwide rights to research, develop, manufacture, ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful ...

Advanz Pharma secures exclusive rights from Alvotech to commercialize three biosimilar candidates in Europe in addition to previously partnered programs The agreement includes proposed biosimilars to ...

Lilly in February announced plans to add four U.S. manufacturing sites at yet-to-be-determined sites as part of a roughly $27 billion investment.

Eli Lilly's growth is impressive, but its current valuation is only justifiable with sustained high growth. Click here to ...

Doctors are also seeing success in treating people with certain liver diseases. Isaacs prescribes GLP-1s for people with a ...

GLP-1 drugs like Ozempic show widespread promise beyond weight loss/diabetes, but cost and supply limit broader adoption.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. The Danish drugmaker on Friday abruptly announced that longtime CEO Lars Fruergaard ...

Novo Nordisk is banking on fresh leadership to help it reclaim the crown in the booming weight loss drug market. Stream Connecticut News for free, 24/7, wherever you are. The Danish drugmaker on ...